chartexchange

Novo Nordisk Wins FDA Approval for Weekly Sogroya in Turner Syndrome

Securities.io | Nov 20, 2026 12:02 PM EST

Novo Nordisk on November 20, 2026 announced that the US Food and Drug Administration approved once-weekly Sogroya (somapacitan-beco) injection for children aged 2.5 years and older with growth failure associated with Turner syndrome. The decision adds a fifth pediatric growth-related use for the long-acting growth hormone and provides an alternative to daily injections. Novo Nordisk described Sogroya as the first and only once-weekly, long-acting growth hormone approved for this population. Its…

Read original article